BioPharma Resources

Investigational drug · Phase 3

RAP-219

Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Focal Epilepsy, Epilepsy, Focal Seizure.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

5

3 still active

All registered trials

6

Any phase or sponsor naming "RAP-219"

First trial start

2024

Oct 10, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "RAP-219", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Focal Epilepsy
  • Epilepsy
  • Focal Seizure
  • Refractory Focal Epilepsy
  • Seizure
  • Focal Onset Seizure
  • Bipolar 1 Disorder
  • Focal Onset Seizures

Approved drugs for the same conditions: Epilepsy and seizures · Bipolar disorder · Neurology · Psychiatry

Largest trials

Live from ClinicalTrials.gov: studies naming "RAP-219" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 3 on PubMed

Also in development for Focal Epilepsy

  • AzetukalnerXEN1101Phase 39 trials

    Xenon Pharmaceuticals Inc. · Focal Onset Seizures, Major Depressive Disorder, Bipolar Disorder

  • BHV-7000Phase 36 trials

    Biohaven Therapeutics Ltd. · Focal Epilepsy, Major Depressive Disorder, Bipolar Disorder

  • Shanghai Zhimeng Biopharma, Inc. · ALS (Amyotrophic Lateral Sclerosis), Focal Epilepsy

  • CB03-154Phase 21 trial

    Shanghai Zhimeng Biopharma, Inc. · Focal Epilepsy

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.